Reata Begins Rolling Submission of Omaveloxolone for FA
Reata Pharmaceuticals has initiated a rolling submission of a new drug application seeking U.S. approval of its experimental oral therapy omaveloxolone for people with Friedreich’s ataxia (FA). In a rolling submission, companies can submit individual sections of the application for review by the U.S. Food and Drug Administration (FDA)…